Evidence map›Paper›PMID 40201769›Full record

ArticleIJID regions2025

A retrospective review of group B streptococcus bacteraemia in Western Sydney, Australia from 2011-2023.

Jimmy Shen, Ravindra Dotel, Clinton M G Colaco

Abstract read
In one paragraph

Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Virulence and resistance adaptation of Streptococcus agalactiae Ib/ST261 infecting bullfrogs in Hainan, China between 2019 and 2023.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jimmy ShenThe University of Sydney, Westmead Clinical School, Sydney, Australia.
Ravindra DotelDepartment of Infectious Diseases, Blacktown Hospital, Sydney, Australia.
Clinton M G ColacoThe University of Sydney, Westmead Clinical School, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to describe the epidemiology, clinical manifestations, management, and outcomes of group B streptococcus (GBS) bacteraemia in a large cohort spanning 13 years. Methods: This retrospective study included patients aged 16 years or older with positive GBS blood cultures obtained from four metropolitan hospitals in Western Sydney, Australia, from 1 January 2011 to 31 December 2023, inclusive. The case details of these positive cultures were reviewed using electronic medical records. Results: A total of 344 patients with GBS bacteraemia were included during the 13-year study period. The median age was 65 years, and 50% of the patients were aged 65 years or older. Known risk factors were identified in 83.1% of the patients with cardiac disease, and diabetes mellitus was the most prevalent. Skin and soft tissue infections were the most common primary manifestation (32.0%). Pregnancy-related infections represented a notable proportion of the cases (16.3%). The 7- and 30-day mortality rates were 2.3% and 5.2% respectively, with a higher mortality rate of 9.3% for those aged 65 years or older. Penicillins were the most common antibiotic class used to treat GBS bacteraemia and its resultant manifestations (66.1%). Conclusions: GBS bacteraemia most commonly occurs in individuals aged ≥65 years or during pregnancy. While mortality rates are generally low, they are twice as high in those aged ≥65 years.

Indexed as

AntibioticsBacteraemiaClinical manifestationEpidemiologyGroup B streptococcusRetrospective reviewStreptococcus agalactiaeSydney, Australia

Identifiers

PMID40201769
PMCPMC11978319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.